Adverse event reporting for cellular therapy products: Current status and future directions

Area of Science:

• Hematology
• Pharmacovigilance
• Biotechnology

Background:

• Adverse event (AE) and adverse reaction (AR) reporting are crucial for patient safety and surveillance.
• Analysis of AE/AR data can improve processes, product information, and patient outcomes.
• Current AE/AR reporting for cellular therapy products lacks centralization and characterization.

Purpose of the Study:

• To summarize the current state of AE/AR reporting for cellular therapy products.
• To identify opportunities for streamlining and coordinating AE/AR reporting.
• To provide a key reference for professionals in the field of cellular therapy safety.

Main Methods:

• This is a review article.
• Authors are experts from various organizations.
• The review synthesizes existing knowledge on AE/AR reporting in cellular therapies.

Main Results:

• Current AE/AR reporting for cellular therapies is fragmented across different systems.
• There are opportunities to enhance data collection, analysis, and sharing.
• Improved coordination can lead to better patient safety and donor protection.

Conclusions:

• Streamlining AE/AR reporting is essential for cellular therapy oversight.
• A coordinated approach will enhance patient safety and product efficacy.
• This review serves as a foundational resource for improving cellular therapy surveillance.